Please use this identifier to cite or link to this item: http://repo.knmu.edu.ua/handle/123456789/18814
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZakharenkova, A.-
dc.contributor.authorВізір, Марина Олександрівна-
dc.contributor.authorVizir, Maryna-
dc.contributor.authorВизир, Марина Александровна-
dc.date.accessioned2017-12-13T09:30:56Z-
dc.date.available2017-12-13T09:30:56Z-
dc.date.issued2017-11-
dc.identifier.citationZakharenkova A. Metabolic drugs in anti-ischemic therapy / A. Zakharenkova // Science and Life : Proceedings of articles the international scientific conference, Skleněný Můstek, Karlovy Vary, Czech Republic, 16–17 November 2017. – Karlovy Vary, 2017. – P. 59–64.ru_RU
dc.identifier.urihttps://repo.knmu.edu.ua/handle/123456789/18814-
dc.description.abstractThe first drugs for anti-ischemic therapy were vitamins of group B, but their effectiveness was refuted in clinical trials. The next drug was trimetazidine, since it has a high cytoprotective effect. This drug is especially effective in patients with stable angina. But thiotriazoline is a new anti-ischemic drug that includes anti-ischemic, metabolic and antioxidant activity with minimal side effects. Summing up, given the good tolerability, efficacy and safety, thiotriazoline can be recommended as a remedy of metabolic therapy for the treatment of IHD in the elderly.ru_RU
dc.language.isoenru_RU
dc.publisherSkleněný Můstek, Karlovy Vary, Czech Republicru_RU
dc.subjectanti-ischemic therapyru_RU
dc.subjectcoronary heart diseaseru_RU
dc.subjectTrimetazidineru_RU
dc.subjectthiotriazolineru_RU
dc.titleMetabolic drugs in anti-ischemic therapyru_RU
dc.typeArticleru_RU
Appears in Collections:Наукові роботи молодих вчених. Кафедра внутрішньої медицини № 1

Files in This Item:
File Description SizeFormat 
Статья Захаренкова.docx25,26 kBMicrosoft Word XMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.